玻璃酸钠联合通痹胶囊治疗踝骨关节炎临床观察.docVIP

玻璃酸钠联合通痹胶囊治疗踝骨关节炎临床观察 　　【摘 要】目的：观察玻璃酸钠联合通痹胶囊治疗踝骨关节炎的临床疗效。方法：将74例踝骨关节炎患者随机分为治疗组38例和对照组36例，对照组采用玻璃酸钠踝关节腔穿刺注射治疗，治疗组在对照组的基础上加服通痹胶囊，两组均以5周为1个疗程，观察两组治疗前后临床疗效及AOFASI评分。结果：治疗组优18例，良12例，可5例，差3例，总有效率为94.74%；对照组优13例，良11例，可6例，差6例，总有效率为83.33%。两组比较，差异有统计学意义（P 0.05）。治疗后，两组AOFAS评分较治疗前均有提高（P 0.01），且治疗组优于对照组（P 0.05）。结论：玻璃酸钠联合通痹胶囊治疗踝骨关节炎具有较好的临床疗效，对踝骨关节炎的治疗有一定临床意义。 　　【关键词】 骨关节炎，踝；通痹胶囊；玻璃酸钠；临床疗效 　　doi：10.3969/j.issn.2095-4174.2015.08.006 　　【ABSTRACT】Objective：To observe the clinical effect of treating ankle osteoarthritis with sodium hyaluronate combing Tongbi Capsule （通痹胶囊）.Methods：74 cases of ankle osteoarthritis were randomly divided into a treatment group （38 cases） and a control group （36 cases）.The control group was treated with sodium hyaluronate injection in the ankle joint，and the treatment group was treated with Tongbi Capsule based on the treatment of the control group.After a course of 5 weeks，the clinical curative effect and the AOFASI score of the two groups were observed before and after treatment.Results：In the treatment group，18 cases were excellent，12 cases were good，5 cases were just OK，and 3 cases were not good，the total effective rate being 94.74%；while in the control group，13 cases were excellent，11 cases were good，6 cases were just OK，and 6 cases were not good，the total effective rate being 83.33%.The difference between the two groups was statistically significant（P 0.05）.After treatment，the AOFAS scores of the two groups were improved than those before treatment（P 0.01），and the treatment group was better than the control group（P 0.05）.Conclusion：Sodium hyaluronate combined with Tongbi Capsule has a better clinical effect in treating ankle osteoarthritis，being clinically significant. 　　【Keywords】 osteoarthritis，ankle；Tongbi Capsule（通痹胶囊）；sodium hyaluronate；clinical efficacy 　　踝骨关节炎（osteoarthritis，OA）是指踝关节由于原发性或继发性等多种原因引起的踝关节软骨表面纤维化、破裂、溃疡、剥脱的关节疾病。原发性OA主要发生于中老年人，无明显外伤或其他疾病而出现的软骨损伤或缺失，考虑与年龄或遗传因素有关。继发性OA的原因包括创伤、炎症、关节不稳定、慢性反复的积累性劳损或先天性疾病等，主要症状为踝关节疼痛及关节活